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T he digitalis glycosides (digoxin) have beenensconced by history, efﬁcacy, therapeuticnecessity, and lack of deﬁnitive evidence
as treatments for both heart failure (HF) and atrial
ﬁbrillation (AF). There is a reluctance to abandon
digoxin because of its perceived ability to additively
improve symptoms and reduce hospitalizations in
HF and to control heart rate in AF when other agents
have failed or have intolerable effect proﬁles (1).
Simultaneously, there is trepidation toward routine
use in HF because of the perception of a narrow ther-
apeutic window and the absence of well-conducted
studies demonstrating an additive effect in a back-
ground of modern pharmacological and device ther-
apy. The use of digoxin in AF as a single or initial
agent is not recommended, but it is sometimes
necessary for rate control when other medications
have failed or hypotension is encountered. Evidence
is emerging that digoxin use in patients with AF
(without HF) may be associated with harm (2–5).
The call for a randomized controlled trial in these pa-
tient populations may be warranted, especially
because of the null or negative effects reported
from observational studies. As with all observational
studies, the true association of a risk factor or treat-
ment with outcomes can only be approximated as
bias and confounders are often present. In the case
of digoxin, patients with more advanced HF, interval
hospitalization, or more recalcitrant AF are more*Editorials published in the Journal of the American College of Cardiology
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HeartWare, Amgen, Novartis, Resmed, and Medtronic.likely to be prescribed digoxin, which is likely to
associate digoxin with worse clinical outcomes.In this issue of the Journal, Allen et al. (6) present
an analysis of a large registry of patients with AF,
some of whom had HF, and some of whom were
treated with digoxin. The investigators took advan-
tage of the wealth of data collected in the registry to
measure the association of digoxin with adverse
outcomes stratiﬁed by HF status. The investigators
rigorously evaluated digoxin’s effects by employing
state-of-the-art analyses designed to mitigate the
confounders and some of the known issues with
propensity matching, which is a surrogate for
randomization. In the present study, there was no
increase in mortality among HF patients treated with
digoxin (prevalent use of digoxin adjusted hazard
ratio: 1.04; p ¼ NS; incident use of digoxin adjusted
hazard ratio: 1.05; p ¼ NS). This result remains true to
the mortality endpoint from the DIG (Digitalis Inves-
tigation Group) trial (6). Prevalent digoxin use and
incident digoxin use were similar and included 1.0 in
their respective conﬁdence intervals, which is an
indication that patients with worsening HF were not
additionally harmed by digoxin itself. The current
study differed from the DIG trial and found no asso-
ciation between digoxin treatment and hospitaliza-
tion rates in patients with HF. The original DIG trial
excluded AF at entry, and the current ﬁndings sug-
gest that AF nulliﬁes the effect of digoxin in reducing
hospitalizations for HF patients. The absence of
beneﬁt or harm associated with digoxin in this pop-
ulation of AF patients with HF adds further credence
to the call for a better understanding of digoxin’s role
in modern HF therapy.
Among patients with AF and without HF, the
investigators reported an increase in deaths, car-
diovascular hospitalizations, and the combination
of death and cardiovascular hospitalization in those
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2700patients with incident digoxin use. This effect could
result from unmeasured confounders or variables
absent from the propensity model, such as inci-
dent hospitalizations, which would also correlate
with a higher incidence of events regardless of
digoxin therapy. However, because of the multiple
adjustments and propensity matching, a truly
harmful effect of digoxin might be present in this
population. Harm from digoxin is consistent with
recent reports from the TREAT-AF (Retrospective
Evaluation and Assessment of Therapies in Atrial
Fibrillation) and ROCKET-AF (Rivaroxaban Once
Daily Oral Direct Factor Xa Inhibition Compared
with Vitamin K Antagonism for Prevention of
Stroke and Embolism Trial in Atrial Fibrillation)
studies (2,3). Currently, no study demonstrating a
beneﬁt of digoxin in this population has been
reported.
Limitations of the present study include the po-
tential for absence of important factors that inﬂuence
digoxin use from the propensity model, such as inci-
dent hospitalizations, imputation of ejection fraction
data in 11% of patients, and lack of information
regarding serum digoxin levels or dosing. Overall,
Allen et al. (6) report perhaps the most rigorously
adjusted analysis addressing the effects of digoxin.
Does the investigators’ work and those of others
establish or create equipoise for a study of digoxin
in HF or AF? For patients with HF with reduced
ejection fraction who are in either sinus rhythm or
AF, there remains an unmet need for therapies that
further ameliorate patient reported symptoms and
reduce hospitalizations. Because of the current pa-
per and the work of others, equipoise exists for
randomization to either digoxin or placebo in a
background of guideline-directed medical therapy.
Equipoise is best established for deﬁning digoxin’s
role as superior to guideline-directed medical ther-
apy alone for reducing hospitalizations or improving
symptoms. A hospitalization endpoint would be
acceptable to clinicians and is reliably measurable.
An absolute reduction in hospitalization of 5% could
be supported as a minimally important treatment
difference. Effects on symptoms would be more
difﬁcult to quantify because of dropouts, but
symptoms can certainly be objectively measured via
exercise testing (6-min walk) or subjectively
measured via validated HF symptom inventories.
Past analyses would also suggest that a novel trial
contain explicit dosing parameters (digoxin
levels <0.8 ng/ml) and have the power to detect a
large difference in response or safety proﬁle be-
tween the sexes. The equipoise for mortality is lesscertain because of the DIG trial results and obser-
vational studies that suggest no trend toward
improved survival in modern samples, including the
current report from the ORBIT-AF (Outcomes Reg-
istry for Better Informed Treatment of Atrial
Fibrillation) registry. Even the original DIG in-
vestigators suggested that digoxin’s effect on mor-
tality is likely “moderate” (7).
The use of digoxin in AF without HF with a
reduced ejection fraction or HF symptoms deserves a
separate evaluation of equipoise because of the re-
sults of the present analysis, other observational
studies, and subgroup analyses of large AF trials. The
argument for routine use of digoxin as an initial
therapy or single agent in AF is weak, although its
use among those with hypotension or following
failure of other atrioventricular nodal blockers is
occasionally necessary. However, designing a trial
that requires treatment failure or the constellation of
parameters favoring digoxin use (e.g., hypotension,
reduced left ventricular function) before randomi-
zation would be exceedingly difﬁcult. In addition,
there is no alternate treatment to which patients
could be randomized. Randomization to placebo or
atrioventricular node ablation and a pacemaker at
this phase of treatment would seem unethical, and
inconsistent with clinical practice and guidelines.
Accordingly, the population of AF patients for whom
equipoise exists at this time is unclear. If one be-
lieves in the harm of digoxin measured in observa-
tional trials, proving this effect may seem warranted
because of the large population at risk for harm, but
the same belief in the trend toward harm, as seen
with incident digoxin use in this study, may preclude
the ability to randomize patients. In the absence of
equipoise or a reasonable trial design, digoxin will
most likely continue to ﬁll a niche as a secondary
therapy for AF, as currently recommended.
The analysis by Allen et al. (7) supports the case for
a novel study to investigate the efﬁcacy of digoxin in
HF patients for the purpose of reducing hospitaliza-
tions and improving symptoms. There remains a need
for digoxin use among selected patients with AF,
while the design and equipoise for a clinical trial in
AF are unclear. Thus, providers may need to accept
200 years of accumulated experience with digoxin to
guide its use as AF therapy.
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